NFE2L2 and neoplasm: However, in certain tumours this pathway is constitutively activated due to gain-of-function mutations in NFE2L2 (encoding NRF2) or loss-of-function alterations in KEAP1 or CUL3, promoting cell proliferation and drug resistance.